Royalty Pharma Taps Academic Veteran to Lead University Outreach — Royalty Pharma plc

Event summary

Greg Raskin, M.D., appointed Senior Vice President, Head of Academic Initiatives at Royalty Pharma effective August 2026.
Raskin joins from Memorial Sloan Kettering Cancer Center where he was Senior Vice President, Technology Development.
New role focuses on academic and non-profit institution outreach and managing the Royalty Pharma Translational Prize.
Raskin brings three decades of experience spanning science, medicine, investing, and technology transfer.

The big picture

Royalty Pharma's appointment of Greg Raskin underscores the growing importance of academic institutions as sources of biopharmaceutical innovation. With universities and research hospitals increasingly at the forefront of drug discovery, Royalty Pharma aims to position itself as a key funding partner. The move comes as traditional venture capital becomes harder to access for early-stage biotech projects, creating an opportunity for specialized financiers like Royalty Pharma.

What we're watching

Academic Engagement: How Royalty Pharma's expanded academic outreach will impact its access to early-stage innovations.
Funding Solutions: Whether Raskin can develop new funding models for cash-strapped academic institutions.
Portfolio Growth: The pace at which Royalty Pharma can convert academic partnerships into royalty-generating products.